Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS: Subanalysis of a phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m2) with two or more comorbidities. Subjects were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated. RESULTS: At baseline, 475 subjects met the criteria for prediabetes and/or MetS. After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo. The ability of PHEN/TPM ER to prevent diabetes was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN/TPM ER was well tolerated by this subgroup over 2 years. CONCLUSIONS: PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a post hoc CONQUER analysis, phentermine/topiramate ER reduced T2D progression by 48–78% over 56 weeks, depending on dose and baseline glycemia, driven by up to 10.9% weight loss and improved insulin sensitivity [26].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This agent induces significant weight loss (10–12%) [26] which may alleviate OA symptoms. However, OA-specific data are lacking, and use remains extrapolative.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The translation of the structured lifestyle intervention used in the Diabetes Prevention Program to community-based programs, commercial programs, and programs using remote technologies have achieved less weight loss than observed in the Diabetes Prevention Program trial itself.861–869”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [865]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A meta-analysis of 44 Diabetes Prevention Program translation studies reported an average 9.3-month weight loss of 3.77 kg from participants’ baseline weight and a decrease in fasting glucose of 2.4 mg/dL.865”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [865]
Experimental — accuracy not yet measuredIn the citing paper
“Phentermine/topiramate ER reduced incident T2DM in patients with prediabetes or metabolic syndrome by 79%.”
From The Vasculature in Prediabetes (2018) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 7×
“The DPP study, wherein patients achieved ;6% mean weight loss at 2 years and ;4% weight loss at 4 years in the lifestyle intervention arm, reported a progressive 16% reduction in type 2 diabetes risk with every kilogram of weight loss but without an indication that there was a threshold of weight loss for maximal type…”
BackgroundMethodInfluentialAlberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Analysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Research works printed but not linked: 2
- 27. Brownell K. The LEARN Program for Weight Management. Dallas, TX, The Life Style Company, 2000
- 40. Garvey WT, Najarian T, Peterson CA. Significant weight loss with controlled-release phentermine/topiramate (PHEN/TPM CR) is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks. Obesity 2011;19:S176
Cited by
Items 101–200 of 219
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Hong, S., Park, J. H., Han, K., Lee, C. B., Kim, D. S., & Yu, S. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab714 · Cited by 34
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“Phentermine/Topiramate ER In a post hoc CONQUER analysis, phentermine/topi-ramate ER reduced T2D progression by 48–78% over 56 weeks, depending on dose and baseline glycemia, driven by up to 10.9% weight loss and improved insulin sensitivity [26].”
InfluentialObesity and type 2 diabetes: Also linked in therapeutic options
Rubio-Almanza, M., Cámara-Gómez, R., & Merino-Torres, J. F. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.006 · Cited by 34
Truong, S. D., Tran, N. Q., Ma, P. T., Hoang, C. K., Le, B. H., Dinh, T., Tran, L., Tran, T. V., Le, L. H. G., Vu, H. A., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s347830 · Cited by 27
“Several studies have shown that subjects with MetS are highly likely to develop type 2 diabetes.(7,8) In tandem, T2DM and MetS are significant healthcare burdens contributing to morbidity and mortality globally, mainly through cardiovascular complications.”
BackgroundSarfati, D., McLeod, M., Stanley, J., Signal, V., Stairmand, J., Krebs, J. D., Dowell, A. C., Leung, W. C. Y., Davies, C., & Grainger, R. (2018) · Trials · doi:10.1186/s13063-018-2528-4 · Cited by 29
Wilkinson, L., Holst‐Hansen, T., Laursen, P. N., Rinnov, A. R., Batterham, R. L., & Garvey, W. T. (2023) · Obesity · doi:10.1002/oby.23842 · Cited by 25
Self-citationA review of the metabolic effects of controlled-release Phentermine/Topiramate
Kiortsis, D. N. (2013) · HORMONES · doi:10.14310/horm.2002.1438 · Cited by 28
Gilbertson, N. M., Paisley, A. S., Kranz, S., WELTMAN, A. L., Kirby, J. L., Hallowell, P. T., & Malin, S. K. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2966-1 · Cited by 25
Wang, W., Wei, R., Huang, Z., Luo, J., Pan, Q., & Guo, L. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3680 · Cited by 23
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
“5/46 and 15/92 mg, respectively, compared with placebo over 108 weeks (Figure 4) [87].”
BackgroundInfluentialCurrent and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.10.001 · Cited by 26
Current pharmacotherapies for obesity: A practical perspective
Golden, A. K. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12519 · Cited by 25
“Pharmacotherapy-induced weight loss has been shown to help lower blood glucose and delay onset of diabetes (Garvey et al., 2014; Nesto, Fain, Li, & Shanahan, 2016; Torgerson, Hauptman, Boldrin, & Sjöströ, 2004).”
BackgroundPan, H., Sun, J., Luo, X., Ai, H., Zeng, J., Shi, R., & Zhang, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1136653 · Cited by 25
“In addition, metformin, which can reduce FBG levels and reduce morbidity and mortality, is an effective means of T2DM prevention and treatment (54).”
BackgroundNesto, R., Fain, R., Li, Y., & Shanahan, W. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1178590 · Cited by 20
“8%.[27] In the XENDOS study,[28] 42% more”
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 20
“22 Consistent evidence shows that obesity management can delay the progression from prediabetes to T2D 22– 24 and ameliorate hyperglycaemia in T2D.”
The role of anti-obesity medication in prevention of diabetes and its complications
Oh, T. J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.3.158 · Cited by 19
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Self-citationExamining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
“Because of the complex interaction between obesity and diabetes, it is difficult to ascertain and quantify independent contributions of obesity and diabetes to morbidity and mortality (Figure 1), and this remains an area of continuing research.18 Regardless, both biomechanical and cardiometabolic disease complications…”
BackgroundSelf-citationMeng, G., Yang, H., Bao, X., Zhang, Q., Liu, L., Wu, H. Y., Du, H., Xia, Y., Shi, H., Guo, X., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.07.028 · Cited by 18
Bao, X., Xia, Y., Zhang, Q., Wu, H., Du, H., Liu, L., Wang, C., Shi, H. B., Guo, X., Liu, X., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12827 · Cited by 17
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes
Goswami, G., Shinkazh, N., & Davis, N. J. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3020595 · Cited by 18
“[ 68–71]”
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 17
Prescription Medications for the Treatment of Obesity
Preiato, V. L., Serban, D. E., Pasquali, R., & Pagotto, U. (2014) · Springer eBooks · doi:10.1007/978-3-319-09045-0_23 · Cited by 15
“groups [12–16].”
Anti-obesity and anti-diabetic effects of L-citrulline are sex-dependent
Bagheripour, F., Jeddi, S., Kashfi, K., & Ghasemi, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122432 · Cited by 14
Ramirez, A. V. G., Filho, D. R., & Filho, I. J. Z. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666191113125247 · Cited by 16
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Pharmacotherapy of obesity in complex diseases
Pulipati, V. P., & Pannain, S. (2021) · Clinical Obesity · doi:10.1111/cob.12497 · Cited by 15
A “Spoonful of Sugar” and the Realities of Diabetes Prevention!
Cefalu, W. T. (2014) · Diabetes Care · doi:10.2337/dc14-0181 · Cited by 12
Type 2 Diabetes Treatment in the Patient with Obesity
Malin, S. K., & Kashyap, S. R. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.007 · Cited by 15
Garber, A. J. (2015) · Endocrine Practice · doi:10.4158/ep14460.ra · Cited by 12
Pharmacotherapy for weight loss
Rueda‐Clausen, C. F., & Padwal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3526 · Cited by 13
Daud, M. H., Yusoff, F. H., Abdul-Razak, S., Baharudin, N., Mohamed-Yassin, M.-S., Badlishah-Sham, S. F., Nikmat, A. W., Isa, M. R., Jamil, N., Nawawi, H. M., et al. (2023) · Digital Health · doi:10.1177/20552076231176645 · Cited by 11
Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus
Wesling, M., & D’Souza, J. J. (2022) · Drugs in Context · doi:10.7573/dic.2021-11-7 · Cited by 10
A lipidome-wide association study of the lipoprotein insulin resistance index
Bagheri, M., Tiwari, H. K., Murillo, A. L., Al-Tobasei, R., Arnett, D. K., Kind, T., Barupal, D. K., Fan, S., Fiehn, O., O’Connell, J. R., et al. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01321-8 · Cited by 10
“Currently, the available interventions for individuals susceptible to T2D can impact IR and delay disease onset [5, 6].”
Trending Modalities in Type 2 Diabetes Prevention
Lundgrin, E. L., & Hatipoğlu, B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf040 · Cited by 8
HDL2/HDL3 Ratio Changes, Metabolic Syndrome Markers, and Other Factors in a Japanese Population
Moriyama, K., & Takahashi, E. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.32896 · Cited by 8
Energy Balance and Weight Loss for Diabetes Remission
Ryan, D. H. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0005 · Cited by 8
“With the advent of medications approved as an adjunct to lifestyle intervention for chronic weight management, efficacy in diabetes prevention has been shown with orlistat (33), phentermine/ topiramate (34), liraglutide (35), lorcaserin (36), and naltrexone/bupropion (37).”
BackgroundSelf-citationColeman, C. D., Kiel, J., Mitola, A. H., & Arterburn, L. M. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.32 · Cited by 8
A call to action on prediabetes
Dugan, J. A., Cantillep, A., Newberry, K., & Shubrook, J. H. (2018) · JAAPA · doi:10.1097/01.jaa.0000545064.33107.8f · Cited by 8
Domecq, J. P., Prutsky, G. J., Elraiyah, T. A., Wang, Z., Mauck, K. F., Brito, J. P., Undavalli, C., Sundaresh, V., Prokop, L. J., Montori, V. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01269 · Cited by 8
Trends in cardiovascular risk factors control among US adults by glycemic statuses, 2007–2018
Yuan, S., Song, C., He, J., Zhang, R., Bian, X., Song, W., & Dou, K. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad080 · Cited by 8
Yang, W., Zhan, M., Li, Z. Y., Sun, X., & Zhang, K. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06634-y · Cited by 10
Farr, O. M., & Mantzoros, C. S. (2017) · Metabolism · doi:10.1016/j.metabol.2016.12.017 · Cited by 8
“The magnitude of these differences was related to amount of weight loss [46], suggesting that the benefits of these combined therapies on prediabetes are related to successful weight loss.”
BackgroundPharmacotherapeutic options for prediabetes
Rendell, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1817381 · Cited by 9
“475 subjects with either prediabetes or metabolic syndrome [60].”
BackgroundGlobal Syndemic of Metabolic Diseases: Editorial Comments
(2019) · Journal of Diabetes and Clinical Research · doi:10.33696/diabetes.1.002 · Cited by 7
The association of obesity with cardiovascular disease risk and risk-enhancing factors
Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.018 · Cited by 6
Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review
Islam, K. N., Islam, R. K., Tong, V. T., Shami, M. Z., Allen, K. E., Brodtmann, J. R., & Book, J. A. (2024) · Cureus · doi:10.7759/cureus.71875 · Cited by 6
“…comorbidity of type 2 diabetes mellitus, and it was found after 106 weeks of low-dose and high-dose PHEN/TPM that the drug combo produced significant reductions of 70.5% in the low-dose group and 78.7% in the high-dose group in the annualized incidence rate of type 2 diabetes mellitus [75].”
InfluentialClinical Management of Type 2 Diabetes Mellitus after Bariatric Surgery
Khanna, V., & Kashyap, S. R. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0537-2 · Cited by 7
Ekeuku, S. O., Azlina, M. F. N., & Chin, K. (2021) · Applied Sciences · doi:10.3390/app11219860 · Cited by 6
“Populations with MetS are five times more likely to develop type 2 diabetes (T2DM) [74,75].”
BackgroundCurrent Options for the Pharmacotherapy of Obesity
Gouni‐Berthold, I., & Berthold, H. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708192630 · Cited by 7
Charrouf, R., Parr, E. B., Hutchison, A. T., Flint, S. A., Teong, X. T., Wittert, G., Vincent, A. D., Brennan, L., Devlin, B. L., Hawley, J. A., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107696 · Cited by 5
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Status of Diabetes Care: “It Just Doesn’t Get Any Better . . . or Does It?”
Cefalu, W. T., Boulton, A. J. M., Tamborlane, W. V., Moses, R. G., LeRoith, D., Greene, E. L., Hu, F. B., Bakris, G. L., Wylie‐Rosett, J., Rosenstock, J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1073 · Cited by 5
Self-citationGoals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes for Both
Perreault, L. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0316 · Cited by 5
Qatar's Silent Epidemic: A Comprehensive Meta-analysis on the Prevalence of Metabolic Syndrome
Aqel, S., Ahmad, J., Syaj, S., Daoud, M. N., & Araiqat, B. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998286706240129074153 · Cited by 5
Pharmacotherapy for Weight Management
Brett, E. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_21 · Cited by 6
Li, J., Reaven, N. L., Funk, S. E., McGaughey, K. J., & Neovius, M. (2015) · Drugs - Real World Outcomes · doi:10.1007/s40801-015-0021-x · Cited by 5
The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes
Hollander, P. A. (2013) · US Endocrinology · doi:10.17925/use.2013.09.02.101 · Cited by 6
Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes
Price, S. A., Le, Q. N., & White, N. D. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617740825 · Cited by 5
Asencio-Barrientos, C., García-Rodas, O., Chang, C. E., Torres-Salazar, L. C., Cifuentes-Alvarado, M. E., & Barrios-Lupitou, L. C. (2022) · Ciencia Tecnología y Salud · doi:10.36829/63cts.v9i1.812 · Cited by 8
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population*
Nadolsky, K. Z. (2018) · Military Medicine · doi:10.1093/milmed/usx074 · Cited by 4
Gharipour, M., Behmanesh, M., Salehi, M., Vaseghi, G., Nezafati, P., Dianatkhah, M., Khosravi, E., Hosseini, M., & Sadeghi, M. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.05.005 · Cited by 4
Adapa, S., Fahey, P. P., Piya, M. K., Birhanu, F., & Atlantis, E. E. (2026) · Obesity Reviews · doi:10.1111/obr.70091 · Cited by 3
Rathor, S., Singh, S., Sharma, N., Zahoor, I., & Bhyan, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13587-3.00012-6 · Cited by 3
Hu, J., Zheng, L., Fan, X., Lang, H., Xie, H., & Lin, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311502 · Cited by 3
Prevalence of Metabolic Syndrome in People with Type 2 Diabetes in Romania
Albajy, M. A., Mihailescu, D. V., Alexandra, M., & Maranda, I. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.115018 · Cited by 3
Garvey, W. T. (2017) · Diabetes Care · doi:10.2337/dci16-0022 · Cited by 3
Self-citationGarvey, W. T., Arathuzik, G., Miller, G. D., & Ard, J. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-24687-1_23 · Cited by 2
Self-citationYang, W., Wen, J., Wu, F., Zeng, H., Guo, B., & Li, G. (2021) · Medicine · doi:10.1097/md.0000000000024812 · Cited by 2
Garvey, W. T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00018-8 · Cited by 2
Self-citationMODERN APPROACH TO THE PREVENTION OF TYPE 2 DIABETES IN THE ELDERLY
Владиславовна, К. О., Bulgakova, S. V., Долгих, Ю. А., Sharonova, L. A., Тренева, Е. В., & Курмаев, Д. П. (2023) · Успехи геронтологии · doi:10.34922/ae.2023.36.4.013 · Cited by 2
Jalisi, A., Jahić, R., Kurtović, A., Đešević, M., Husić-Selimović, A., Hodžić, E., Salčin, E. L., Lepara, O., & Fajkić, A. (2024) · Cureus · doi:10.7759/cureus.63389 · Cited by 2
Pharmacotherapy of obesity: State of the art and perspectives
Sićović, K., & Micov, A. M. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50625 · Cited by 3
Cefalu, W. T., Buse, J. B., Tuomilehto, J., Fleming, G. A., Ferrannini, E., Gerstein, H. C., Bennett, P. H., Ramachandran, A., Raz, I., Rosenstock, J., et al. (2017) · Diabetes Care · doi:10.2337/dci16-0036 · Cited by 2
Baloch, H. M., & Nadolsky, K. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0125 · Cited by 1
Perreault, L. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_2 · Cited by 1
Qarni, A. A. A., AlSubaiee, M., Husain, M., Alkhazmari, G., AlQahtani, A., Aldossary, I., Gado, W., Albahrani, Z., AlMukhaylid, S., Alarfaj, A., et al. (2023) · Series of Endocrinology Diabetes and Metabolism · doi:10.54178/jsedmv5i2004 · Cited by 2
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
International consensus on adolescent metabolic health: prevention of obesity and type 2 diabetes
Shaltout, I., Schwarz, P. E. H., Meligi, A. A. H. E., Sherif, I. E., Hammad, H., Abdelghaffar, S., Hegazy, M., Nasr, G. M., Habeeb, H., Barakat, E., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02142-y · Cited by 2
“A low-dose combination therapy provides synergistic and safer weight reduction [102, 103] and reduces the incidence of new-onset T2D over two years [104].”
Wasityastuti, W., Pramaningtyas, M. D., Wibowo, R. A., Adnan, M. L., Prabowo, R., Tsurayya, Z., Dhamarjati, A., Nugroho, J. P. A., Wangiyana, N. K. A. S., Bhagat, O. L., et al. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006174 · Cited by 1
Nutrition Therapy for the Prevention and Treatment of Prediabetes and Diabetes
Franz, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-43027-0_8 · Cited by 1
Hypertension and Dyslipidemia in Patients with Pre-Diabetes
Tsimihodimos, V., & Florentin, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00013-2 · Cited by 1
Dysglycemia-based Chronic Disease—Diabetes Re-worked
Mechanick, J. I. (2018) · US Endocrinology · doi:10.17925/use.2018.14.2.77 · Cited by 1
Kim, J. D., & Lee, W. (2020) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2020.2.e10 · Cited by 1
Individualizing Lifestyle Therapy for Patients with Obesity
Garvey, W. T. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)43231-8 · Cited by 1
Self-citationFATORES DE RISCO PARA SÍNDROME METABÓLICA EM ADULTOS NO BRASIL
SILVA, M. L. D. S. D., NASCIMENTO, G. A. D., & BRAZ, N. B. P. (2024) · Revista Científica Semana Acadêmica · doi:10.35265/2236-6717-243-12930 · Cited by 1
Zhang, Y., & Li, A. (2025) · Open Medicine · doi:10.1515/med-2025-1184 · Cited by 1
“E ff ective weight management in obese individuals delays the progression from prediabetes to diabetes [41] and provides signi fi cant therapeutic bene fi ts for T2DM [42].”
Rubio-Almanza, M. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.664939 · Cited by 2
Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges
Aroda, V. R., & Getaneh, A. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1054280
“5/46 and 15/ 92 groups, respectively [93].”
Grunberger, G., Abelseth, J. M., Bailey, T. S., Bode, B. W., Handelsman, Y., Hellman, R., Lane, W. S., Raskin, P., Tamborlane, W. V., & Rothermel, C. (2014)
La prevención de la diabetes tipo 2. Muchas aristas y el peso como cuestión central
Bueno, E. (2015) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2015.02(01)08-010
Das pharmakologische Management von Adipositas
Toplak, H. (2016) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citationPharmacological management of obesity in patients with type 2 diabetes
Black, R. L., Higbea, A. M., Duval, C., & Chastain, L. M. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1220300 · Cited by 1
“It may also help with lowering blood glucose and progression to type 2 Diabetes, as well as blood pressure [25,27,28].”
BackgroundObesity and the Risk for Type 2 Diabetes
Bray, G. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00030-8
Evaluation and Treatment of Insulin Resistance and Hyperglycemic States
Hurley, D. L., & Zangeneh, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_13
Metadata
- Authors
- Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W.
- Affiliations
- University of Alabama at Birmingham (US)
- Pennington Biomedical Research Center (US)
- University of California San Diego (US)
- Monteagle Medical Center, San Francisco, CA
- Medical University of Graz (AT)
- Medpace (United States) (US)
- Vivus (United States) (US)
- Corresponding author
- Garvey, W. Timothy
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-03-08
- Volume
- 37
- Issue
- 4
- Pages
- 912-921
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4392900
- OpenAlex
- W2149822561
- Cited by
- 215
- References
- 42
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 17 · 2023: 20 · 2022: 14 · 2021: 16 · 2020: 19 · 2019: 17 · 2018: 22 · 2017: 16 · 2016: 14 · 2015: 20 · 2014: 15
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01CX000432)
- National Institutes of Health (5p60dk079626-05)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK-079626, P30DK079626)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes prevention, prediabetes, metabolic syndrome, obesity, weight loss, cardiometabolic risk factors, lifestyle modification, glycemic control, lipid profile, blood pressure, waist circumference
- MeSH terms
- Topiramate, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Female, Fructose, Humans, Life Style, Male, Middle Aged, Phentermine, Placebos, Prediabetic State, Anti-Obesity Agents, Metabolic Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.